Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 7:02 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2209–2232 of 3,106 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Treatment of depression Clear all

Conditions: Major Depressive Disorder
Interventions: Placebo, Ketamine; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 13
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Centennial, Colorado + 10 more

Conditions: Depression, Anxiety
Interventions: Emotionally Focused Therapy for Individuals, Self-Help CBT Training; Behavioral
Lead sponsor: Saint Paul University; Other
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Treatment-Resistant Depression
Interventions: Not listed
Lead sponsor: Mclean Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2012
U.S. locations: 1
States / cities: Belmont, Massachusetts

Conditions: Depressive Symptoms, Major Depressive Disorder, Recurrent, in Remission
Interventions: Be Mindful; Behavioral
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 18 Years to 65 Years
Enrollment: 137 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Depression, Cardiovascular Diseases
Interventions: BA-HT, Standard Care; Behavioral · Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 21 Years and older
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Adolescent Behavior
Interventions: As Safe As Possible, Brite, Treatment as Usual; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 12 Years to 17 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania • Dallas, Texas

Conditions: Depressive Disorder, Major
Interventions: GSK561679, Placebo; Drug · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 64 Years · Female only
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 18
States / cities: Cerritos, California • San Diego, California • Torrance, California + 15 more

Conditions: Depression
Interventions: Transcranial direct stimulation; Device
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 75 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Opioid Use Disorder, Substance Use Disorders, Medication Assisted Treatment
Interventions: Minds and Mentors, Twelve Step Intervention Group; Behavioral
Lead sponsor: University of Alabama, Tuscaloosa; Other
Eligibility: 19 Years and older
Enrollment: 240 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 4
States / cities: Birmingham, Alabama • Tuscaloosa, Alabama

Conditions: Depression
Interventions: Growth Mindset; Behavioral
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 11 Years to 25 Years
Enrollment: 4,100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2027
U.S. locations: 3
States / cities: Los Angeles, California • Denver, Colorado • Bethesda, Maryland

Conditions: Chronic Pain
Interventions: Cognitive Behavioral Therapy (CBT), Hypnotic Cognitive Therapy (HYP-CT), Mindfulness-Based Cognitive Therapy (MBCT); Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 331 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 3
States / cities: Seattle, Washington • Tacoma, Washington

Conditions: Neurobehavioral Components of Reward and Loss Valuation
Interventions: cognitive behavioral therapy, valuation with instruction, valuation without instruction; Behavioral
Lead sponsor: Virginia Polytechnic Institute and State University; Other
Eligibility: 25 Years to 50 Years
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Roanoke, Virginia

Conditions: Depression
Interventions: Scopolamine and naltrexone, placebo arm; Drug
Lead sponsor: The Taub Group; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Depression, Mild Cognitive Impairment
Interventions: IV Ketamine; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 50 Years to 90 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Bipolar Disorder, Major Depression
Interventions: Selective Serotonin Reuptake Inhibitor (SSRI); Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 15 Years to 30 Years
Enrollment: 192 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2018
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Major Depressive Disorder, Depression, Depressive Disorder, Depressive Episode, Depression, Unipolar
Interventions: GeneSight Psychotropic test, FDA-approved antidepressant or antipsychotic treatment; Other · Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 65 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Depression
Interventions: Ketamine; Drug
Lead sponsor: Loma Linda University; Other
Eligibility: 18 Years to 89 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: Substance Use Disorders, Parent-Child Relations, Parent Child Abuse
Interventions: MIO-CPP; Behavioral
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: Female only
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Anxiety Disorders
Interventions: Transdiagnostic Telenovela Intervention; Behavioral
Lead sponsor: University of Nevada, Reno; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Reno, Nevada

Conditions: Major Depressive Disorder
Interventions: agomelatine, placebo; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 508 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 42
States / cities: Scottsdale, Arizona • Little Rock, Arkansas • Cerritos, California + 38 more

Conditions: Rumination, Worry, Self-Criticism, Anxiety, Depression, Distress, Emotional
Interventions: Emotion Regulation Therapy via Telehealth; Behavioral
Lead sponsor: Teachers College, Columbia University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Internalizing Psychopathologies (IPs) Depression and Anxiety
Interventions: SSRI, CBT; Drug · Behavioral
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years to 65 Years
Enrollment: 271 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Depressive Disorder, Major
Interventions: Rapastinel, Placebo; Drug
Lead sponsor: Naurex, Inc, an affiliate of Allergan plc; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 658 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 66
States / cities: Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 56 more

Conditions: Osteoarthritis, Knee
Interventions: Progressive resistance exercise; Procedure
Lead sponsor: Indiana University; Other
Eligibility: 60 Years and older
Enrollment: 280 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1977 – 2006
U.S. locations: 1
States / cities: Indianapolis, Indiana

Search by objective public record fields.

A Study of Ketamine in Patients With Treatment-resistant Depression

An Attachment Based Approach for Anxiety and Depression

Functional and Neurochemical Correlates of Treatment Response in Major Depressive Disorder

The Effects of the Be Mindful Intervention in Previously Depressed Individuals Experiencing Subclinical Symptoms

Behavioral Activation Delivered Via Home-based Telehealth to Improve Functioning in Cardiovascular Disease Patients Recently Discharged From Inpatient Care

Brief Intervention for Suicide Risk Reduction in High Risk Adolescents

A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive Disorder

Adjunctive Transcranial Direct Current Stimulation for Cognition in Major Depression

Minds and Mentors Program- R33

Characterization and Treatment of Adolescent Depression

Matching Adults to Treatments for Chronic Pain (MATCH) Study

Valuation in Depressed Mood, Anhedonia, and Anxiety

The Safety and Efficacy of Naltrexone and Scopolamine Utilized in the Treatment of Major Depression

Single-dose Ketamine Treatment to Improve Depression in Mild Cognitive Impairment

Differentiating Unipolar and Bipolar Depression in Young Adults Using fMRI

Combinatorial Pharmacogenomics Testing in Treatment-Naïve Major Depressive Disorder

Low Dose Ketamine Infusion for the Treatment of Resistant Depression

MIO-CPP to Improve the Well-being, Permanency, and Safety Outcomes for Young Children at Risk of or in Out-of-home Placement in Philadelphia and Bucks Counties, and Affected by Maternal Substance Use

Reducing Mental Health Disparities Among Latinxs With a Telenovela Intervention

Efficacy, Safety and Tolerability of Agomelatine in the Treatment of Major Depressive Disorder

Readiness and Progress in Emotion Regulation Therapy

Negative Valence Brain Targets and Predictors of Anxiety and Depression Treatment

A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-02)

Effects of Strength Training on Knee Osteoarthritis